Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- Scalp Cooling Device Associated With Less Alopecia After Chemotherapy for Breast Cancer
- Utidelone Plus Capecitabine vs Capecitabine Alone for Heavily Pretreated Metastatic Breast Cancer Refractory to Anthracyclines and Taxanes
- Zoledronic Acid Every 12 Weeks Is Noninferior to Every 4 Weeks in Women With Breast Cancer Metastatic to Bone
- Zoledronic Acid Every 12 Weeks Is Noninferior to Every 4 Weeks in Women With Breast Cancer Metastatic to Bone
- Longer-Interval Dosing of Zoledronic Acid Effective in Patients With Bone Metastases
- Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
- Pegylated Liposomal Doxorubicin vs Capecitabine as Effective First-Line Therapy for MBC
- Breast Cancer Screening: Tumor Size and Overdiagnosis
- Increased Cognitive Difficulties in Breast Cancer Survivors After Chemotherapy
- Optimal Timing of Influenza Vaccination During 3-Week Cytotoxic Chemotherapy Cycles